Posted by AGORACOM-JC
at 9:21 AM on Monday, January 6th, 2020
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
Teas and edibles and vapes, oh my!
By: Kyle Mack
The latest in cannabis products will be available for legal sale in Ontario.
The Ontario Cannabis Store (OCS) is releasing 59 new products
including edibles, beverages, lotions, and concentrates in stores today
but online Jan 16.
Prices of edibles range from $7.50 to $16 per item while beverages
can cost between $4 to $10 and vapes falling between $25 – $125. Daniel
Safayeni, Director of Policy at The Ontario Chamber of Commerce has
previously released a statement on the THC limit per edible stating,
“The OCC supports a THC limit of 10-milligrams per discrete unit of
edibles, as well as the sale of multi-packs or multiple products—up to a
maximum of 100-milligrams of THC per package—within child-proof
packaging. As we outline in the report, single-packs are costly, while
multi-packs would allow licensed producers to create economies of scale.
The proposed regulations, however, limit the amount of THC per package
to only 10 milligrams, which is significantly lower than illegal
alternatives and lower in other U.S. jurisdictions where recreational
cannabis is legalâ€.
The THC cap may act as a barrier to shifting cannabis shoppers from
making illicit purchases, where higher THC contents can be found.
Posted by AGORACOM-JC
at 2:38 PM on Friday, January 3rd, 2020
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
Edibles, vapes and tea coming to legal Ontario cannabis shops Monday
Ontario’s cannabis distributor says dozens of new marijuana products will be available in retail shops starting Monday but supplies will be limited.
Unveiled 59 new items today including a variety of vapes, edibles and a tea.
TORONTO – Ontario’s cannabis distributor says dozens of new marijuana products will be available in retail shops starting Monday but supplies will be limited.
The Ontario Cannabis Store unveiled 59 new items today including a variety of vapes, edibles and a tea.
The products will be available in the province’s legal cannabis
retail stores starting next week and Cannabis edibles to hit store
shelves in January.
The distributor estimates that products will be in short supply until March as manufacturers ramp up production to meet demand.
The number of products will grow to 100 in the coming months as they receive regulatory approval.
The OCS says the new selection will help it combat black market sales across the province.
It was exactly a year ago that the Farm Bill legalized CBD and hemp,
the latter a cousin to cannabis as it comes from the same plant. Of
course, there were specified guidelines, such as hemp can be sold as
long as the maximum THC (the psychoactive compound in cannabis that
gives users their high) count is .3 percent; anything that contains more
will be federally classified as illegal marijuana.
The legalization has spawned a booming cottage industry. But just
like with the federally illegal cannabis market, problems proliferate
for CBD and hemp entrepreneurs. For one thing, many vendors, retailers,
advertisers, manufacturers and banks are still not fully apprised that
hemp, for instance, is legal. Because of this misunderstanding, these
prospective partners balk at working with hemp entrepreneurs, thinking
they’ll be subject to the same penalties they would working with
cannabis businesses.
CBD has not been immune to these setbacks, either. Despite its
legality, the FDA has clamped down on businesses that sell CBD as food
additives or label it as a dietary supplement. According to the food
watchdog, CBD’s safety for use in human or animal food is inconclusive,
requiring more data until proven otherwise.
In a press release, Patrick McCarthy, CEO and co-founder of ValidCare,
a provider of market intelligence and research for the hemp-derived
product industry, offered a few intriguing predictions for the space in
2020. Do you agree? Please let me know.
Safety Product Assurance
“Today’s consumer cares about where the products they put in, and on,
their bodies come from. From big breweries to boutique ice creams,
mainstream brands showcase their farmers in their advertising and market
organic, cruelty-free and hyper-local manufacturing practices on their
packaging to assure consumers their products are natural, safe and worth
a premium price. This trend will hit the hemp industry next, as
consumers demand information on plant origin, farming practices, product
composition and sustainability.â€
Baby Boomer Consumption Escalates
“The AARP crowd is one of the largest demographics using hemp-derived
CBD for chronic joint pain and sleep. Expect this trend to increase as
Boomers seek to replace prescription and OTC pharmaceuticals with
hemp-derived products — and to lobby for coverage and/or reimbursement
through FSAs, HSAs and supplemental MediCare policies.â€
Hemp As Mental Health Aid
“Today, one in five Americans report they use hemp-derived CBD for
‘mental health reasons’ such as anxiety. In 2020, we’ll see even more
people ditch Prozac prescriptions for non-impairing hemp-derived CBD to
support their mental health goals. Expect brands targeting this audience
to commission research on hemp-derived CBD’s functional benefits for
mental health.â€
Paving The Way For Minor Supplements
“CBD was this decade’s craze, but as the market for cannabidiol
becomes oversaturated, product companies will introduce other
interesting minor cannabinoids like CBN and CBG, already touted as
having functional benefits tied to sleep and appetite. Expect the FDA to
voice concerns about these ‘cannabis derived compounds’ and mirror its
communication to industry and the public about the need for these
products to be properly vetted for safety and use – and for product
companies to market them nonetheless.â€
Invasion of the Great White North
“Last year we witnessed a number of marijuana companies diversifying
products and risks by introducing hemp-based wellness lines. In 2020,
expect our Northern neighbors to take advantage of the depressed
financial market and invest or buy U.S.-based hemp companies as a way to
enter the U.S. market.â€
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Recently launched CBD extraction facility
First extraction system capacity = 6,000 Kg per year.
CBD based products are poised to be a $20B global industry by 2022
Medical cannabis is poised to be a $100B global industry by 2025
CBD 2020 Outlook: How the Cannabidiol Forecast Looks in the New Decade
The 2020 outlook for CBD forecasts a beautiful and bright upside with a slight chance of raining on the cannabis oil craze parade
As 2019 made cannabidiol a household name, what will the new decade bring in terms of new cannabinoids CBG, CBN and THC-V discoveries, science and regulatory advancements
Cannabidiol, or CBD, won the supplement ingredient of the year by surpassing all other herbal extracts and products in the world in terms of popularity, demand and sales. The impressive rise of CBD cannabis oil extract has been quite an adventure in the past few years and seems to only have more upside in 2020 and beyond.
It was only a year ago now, where the 2018 Farm Bill was passed that
legalized hemp-derived cannabidiol and essentially opened the floodgates
to all kinds of oils, edible gummies and skincare
to name a few. And now, many are projecting the CBD use to continue to
grow in demand, projecting it to be a $22 billion dollar industry by
2022/2023.
The 2020 CBD forecast calls for a bright, sunny and green landscape
as the next few years are set to be highly lucrative and innovative for
the coveted cannabis oil substance. However, let’s focus on the smaller
scope of its industry and talk about the 2020 CBD outlook before we
attempt to paint a ten year prediction.
First, a recap of what happened in 2019, where the CBD craze in
America and the world really picked up momentum, and then a peak around
the corner as to what can happen in 2020 as science, commercial and
consumer interest intensifies across the globe as legal barriers come
down and studies reveal results.
Let’s paint a picture of where CBD is today and what the first year
of a new decade can bring to the emerging cannabis (hemp and marijuana)
markets.
Year 2019 – Strides in CBD
This year came with a lot of major changes for the CBD industry as it
rose to the top of the charts for being the most popular and sold
herbal ingredient. It was the first full year that hemp-based CBD was
legalized after the 2018 Farm Bill, which introduced a wild world of
controversies and other issues, though there have been many supporters
to make big changes. For instance, the legalization of CBD alone has
spurred substantial cannabis reform efforts.
In 2019, cannabis reform legislation was brought forth by 27 states for either recreation or medical use. Arizona was one of the most major states to push for these changes and will see legal recreational use on next year’s ballot. Florida joins Arizona in the efforts, though Mississippi
is amongst the few states that have still yet to legalize medical
marijuana, which could change with this year’s proposal. Other states included in this list are Nebraska, Idaho, New Jersey, Pennsylvania, and more.
Politically, many Democratic presidential hopefuls have discussed
legalization, but Bernie Sanders released a comprehensive plan that
would effectively legalize state and federal marijuana use, while
pushing for the expungement of marijuana-related convictions. The plan,
released in October, would take place within 100 days of taking the
presidential office, if Sanders were to be elected.
Lowell Farms was part of the substantial progress of 2019, launching
the first cannabis cafe to ever reach the US market. Located in California,
the new restaurant has been created to offer a safe public place to
cannabis users, while still offering an area for non-users of the
substance. While partaking, patrons can snack on a variety of infused
dishes, including everything from the grilled peach salad to a cold
beer.
Experts from Brightfield believe that this year will reach $5 billion
in the CBD industry for sales alone, increasing by over 2,500% since
2015. The growth that happened this year has been almost unbelievable
and, while 2019 may have come with a few bumps, there have been major
milestones reached by the new industry. But what’s next?
Year 2020 – What’s Coming for CBD?
The cannabis industry already saw a surge in the number of states
seeking legalization, so what might happen to them next? Since 1996,
medical use of cannabis has already been approved by 33 states, and a
third of those states pushed forward even further by legalizing
recreational use. Many huge votes will take place in 2020, and experts
at CBD Origin predict that several states will end up legalizing
recreational cannabis as a result of CBD’s influence – New York, New Mexico, New Jersey, Arizona, Idaho, and Arkansas.
While Florida is still gathering signatures for the Florida Marijuana
Legalization Initiative, it appears as though the efforts will fall
short, meaning that the proposal probably won’t even be on the ballot.
Missouri could end up on the ballot with enough signatures by May 3rd,
the support from local voters has not been strong enough to provide a
clear idea of which side they will choose. South Dakota, while it pushed
to add cannabis legalization to the ballot, fell short, as did Ohio.
The Effects of Regulation on Quality
Right now, there’s a substantial missing piece in the CBD industry –
regulation. Without regulation, many consumers are fearful of even
getting involved, since there are many companies that are publicly
dishonest with their business practices. As a result, there are only a
few brands that can even prove their product’s potency. Based on the
predictions of CBD Origin, it is likely that the public will aim to
learn more about CBD with its legalization, seeking out higher standards
and greater transparency from companies.
Along with the demand for lab tests to come with higher standards,
consumers will likely give more attention to terpenes and cannabinoids.
This information allows consumers to learn more about the products that
they choose, and a common theme throughout the CBD industry will likely
be the desire for quality products and honesty.
New Options and Less Vaping
As CBD blends become more diverse, and as the industry progresses,
the innovations in the market will likely lead to new options for
consuming CBD. Brands will be pushed to offer more value and benefits to
remain competitive, and additional markets will likely be developed to
push for this grown.
With these new options, especially as consumers seek to be excited
about these opportunities, prominent media outlets are predicting that
the strains available to consumers will likely see an extended “dessert
craze,†as products like Gushers and Runtz become more appealing flowers
than the savory flavors, like GMO Cookies. However, with this
opportunity, there’s a chance that CBD will be seen as more of a potent
medicine and wellness product, rather than a recreational option.
Basically, consumers will start to understand what is offered to them
more effectively.
Vaping became a big concern in 2019, and many industry experts and
authoritative publications don’t believe the heat is wearing off any
time soon. Multiple states have already implemented bans, regardless of
the use of cannabis or tobacco vaping products, which will probably push
users to choose edibles and natural options instead. The idea of a
clean and tamper-proof product will be in higher demand. While the FDA is expected to impose on the industry with new vaping regulations, it may still survive at a minuscule level.
Ethical Practices
The CBD market is still filled with a lot of “unknown†factors,
regarding what is actually in the products that consumers use. After
all, this industry is still very new, and the creation of proper
guidelines was rather difficult as the industry started to expand. There
were many brands that manage to have integrity in their work with
ethical business practices, but there are even more brands that directly
went the opposite direction.
Mark Case, the founder and CEO of the International Hemp Auction and
Market in Knoxville, Tennessee, makes a good point about the way that
the market has changed, warning,
“2020 is not a year for gamblers. Rather, it will be successful only
for those who are wise and prudent, fully integrated and who work with a
good business plan to go the long haul.â€
Unethical business practices will likely be more heavily criticized
and regulated through the next year, as consumers start to expect more
reliable lab testing and authentic lab reports with new regulations.
Consumers have educated themselves, and it will become harder to fool
that average CBD user.
CEO of Validcare, Patrick McCarthy, pointed out,
“The U.S. consumer is going to wake up to the fact that certification
and dosing matters. They’re going to get particular, where they’ve been
trying things in the past. They’re going to start really paying
attention to, what is the product I’m taking? How do I know that it’s
safe? How do I know how much that I should take, and who says it’s
safe?â€
Since the market is projected to be more effectively regulated, it
wouldn’t be a stretch to say that major brands and retailers will be
prepared to get involved. The market alone is set to reach over $25
billion by 2025, and companies like Walmart, Amazon, and Whole Foods will likely want a piece of the action.
Move Over CBD, Make Room for CBG, CBN and THC-V Cannabinoids
CBD became the cannabis industry’s global leader in recognition,
sales and popularity – but what about any of the 100 plus cannabinoids
found in marijuana and hemp plants? The new decade may lead with CBD as
the prized cannabis compound, but there are a few cousin cannabinoids
like CBN, CGB and THC-V which may follow CBD’s growth path.
As mentioned, with the passing of the Farm Bill last year and the
constant mention of cannabis in politics, pretty much everyone has
already heard of CBD by now. The non-intoxicating substance comes from
both hemp and cannabis, and it is touted as a solution to wellness,
pain, and a million other purposes. Even when its popularity and
niche-ness wears off, CBD will likely remain a staple of this industry,
just like THC. However, THC and CBD are two of over 100 cannabinoids
that presently exist in the cannabis plant, and others could easily line
up to offer benefits to the public, according to the latest science and
research.
CBG, or cannabigerol, is considered to be the “mother cannabinoid,â€
earning the nickname because nearly all other cannabinoids that are
presently known start with CBG as their preceding letters. Ultraviolet
(UV) light transforms a part of CBGA that then becomes CBCa, CBDA, or
THCA.
The creators of the various cannabinoids and cannabis strains haven’t
been very interested in maximizing this compound since its presence
inherently means that there is less THC. While cannabinoids largely have
the same properties, CBG seems to offer an elevated antibacterial,
antispasmodic, and vasodilation effect, which is why it is the first one
on this list to watch out for. While there’s a possibility that CBG
could take CBD’s place, it is equally likely that the two will be able
to coexist for their various purposes.
CBG has a unique ability to become something much different than its
natural state, according to some growers. Though THC is restricted by
the percentage it offers in a cannabis plant, CBG is not governed by the
same rules, and breeding a genotype with high CBG levels is relatively
easy, as is harvesting it. With the right synthase, making CBG into
multiple other cannabinoids is simple for producers.
CBN, or cannabinol, is another cannabinoid getting a lot of
attention. CBN comes from the degradation of THC-A, which happens as a
result of air and UV light exposure. Part of the reason that attention
has been on this cannabinoid has been for its ability to push users into
sleep, which is why old cannabis tends to make users tired. A dose of 5
mg of CBN was found to be as effective as a 10 mg dose of Diazepam in
making consumers fall asleep. Sleep concerns are among the most common
reasons for non-users to take up cannabis.
THC-V, or tetrahydrocannabivarin, may be currently popular, but it
was originally recognized in 1970 as “skinny weed,†since it helps to
reduce the user’s appetite. It suppresses the CB1 receptor, while THC
and CBG tend to stimulate the appetite. When used with the proper
timing, it can balance the effects of THC and improve insulin
resistance.
Unlike CBD, THC-V offers a clear and focused high with the right
dose, albeit short-lived. There’s very little research on the
cannabinoid, but the information available suggests that the dosage
seems to be the key to actually getting all of the effects that this
compound can offer. With a dose of 3 mg to each kilogram of body weight
in mice, insulin resistance improved, and weight loss was stimulated.
For the average adult, that would mean a 200-mg dose is necessary, which
seems rather difficult to reach in the market today. However, if the
market shifts to the need for this cannabinoid, access to this much
THC-V may become a reality.
For consumers that prefer the lack of intoxication that they get from
CBD, the use of THC-A may hit the spot. This variation of THC is in the
acid form, which basically means that it is structured the same way as
THC before being heated. Research shows that this variation is highly
effective in reducing inflammation, and it offers both neuroprotective
and anti-cancer effects. Plus, the user can take high doses without the
risk of feeling intoxicated.
THC-A has earned a lot of accolades from medical circles, which
source the compound from juicing either fresh or frozen cannabis fan
leaves. Many people believe it is easiest to source THC-A from this
state, comparing it to other foods with broader nutritional profiles
that preserve their nutrients by avoiding heat and creating cold-pressed
juices.
Even the biggest fans of CBD and THC could end up finding a new
favorite as the industry progresses. The stigma surrounding cannabis is
slowly dying down, and the broad legalization happening throughout the
country will likely pave the way for researchers to learn and develop
more options for the public to try.
Get Ready 2020, CBD Is Coming!
It is clear CBD made its mark in 2019, becoming a household name and
topping the charts in terms of most herbal supplement sales. As the
election year begins the new decade, the 2020 CBD outlook has many
catalysts that could kickstart the new calendar year off in a big way.
From new CBD product research and develop innovations
(applications/product types), to accumulating scientific studies and
supportive medical literature, to regulatory clarity and beneficial
policy updates, to advancing third-party lab testing verification and
certification of analysis proof standardization, cannabidiol is bound to
have an incredible 2020 year as the cannabis green rush powers onward
into the new decade.
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Recently launched CBD extraction facility
First extraction system capacity = 6,000 Kg per year.
CBD based products are poised to be a $20B global industry by 2022
Medical cannabis is poised to be a $100B global industry by 2025
Marijuana On The 2020 Ballot: These States Could Vote
By:Tom Angell
Ever since Colorado and Washington became the first two states to
approve marijuana legalization initiatives in 2012, additional states
have joined them in each biennial election that has followed. And 2020
could be a banner year for cannabis on the ballot.
There are at least 16 states where advocates believe marijuana
measures could go before voters next year—some considering full-scale
recreational legalization while others would focus on medical cannabis.
Getty
Some of these would be citizen-led voter initiatives where activists
collect signatures to qualify a measure for the ballot, while others
would be referendums that lawmakers place before voters.
“Since the first adult-use legalization ballot initiative victory in
2012, the marijuana reform movement has successfully maintained its
momentum,†Matthew Schweich, deputy director of the Marijuana Policy
Project, said. “For four elections in a row there has been a
legalization victory at the ballot box, and the upcoming election could
deliver more victories in one day than ever before.â€
Of course, not every initiated effort will end up securing enough
funding, or formulating solid enough campaign plans, to collect
sufficient signatures to qualify their measures for voters’
consideration on Election Day—but these are all states where activists
or lawmakers have talked seriously about putting cannabis questions on
ballots.
It’s not feasible to list every measure that activists took the
modest trouble to initially file, and this overview looks primarily at
efforts that seem most poised to advance. This post also doesn’t include
the long list of states that might legalize marijuana through actions
by lawmakers, as opposed to citizens via the ballot—which will be the
focus of a separate piece.
In alphabetical order, here’s a comprehensive overview of the states where marijuana could be on the ballot in 2020.
Arizona
Voters in Arizona narrowly rejected a marijuana legalization measure
in 2016, thanks in part to sizable campaign contributions from the
pharmaceutical industry. In 2020, though, the state’s medical
cannabis companies will be working to pass an initiative making marijuana legal for adults.
The effort, known as Smart & Safe Arizona,
would allow people 21 and older to possess, consume, cultivate and
purchase cannabis from licensed retailers. It would also create a
pathway for individuals with prior convictions to have their records
expunged, and it proposes using some tax revenue from legal sales to
invest in communities disproportionately impacted by prohibition.
Dispensary chains MedMen, Harvest Health and Recreation and Curaleaf
Holdings are helping to fund the campaign. Advocates must collect
237,645 valid signatures from voters by July 2 in order to put the
measure on the ballot.
Arkansas
In 2016, Arkansas voters approved a constitutional amendment allowing
patients to have legal access to medical cannabis. Now, activists are
floating separate measures to more broadly end marijuana prohibition and expunge past records.
In order to place the measures on the ballot, Arkansans for Cannabis Reform must gather 89,151 signatures by July 3, including required minimums in at least 15 counties.
Under the legalization proposal, adults over 21 would be allowed to
to possess up to four ounces of marijuana, two ounces of cannabis
concentrate and edible products containing cannabis with THC content of
200 mg or less. They could also cultivate up to six cannabis seedlings
and six cannabis flowering plants for personal use.
A system of legal and regulated sales would be created, with tax
revenue funding the program’s implementation, public pre-kindergarten
and after school programs as well as the University of Arkansas for
Medical Sciences.
Under the separate expungements measure, people with certain prior
marijuana convictions would be able to petition courts for relief,
including release from incarceration, reduction of remaining sentences
and restoration of voting rights.
But while Connecticut doesn’t have the initiative process where
activists can collect signatures to place a question on the ballot, some
elected officials have floated the idea of advancing a referendum that
would let voters weigh in on ending prohibition.
Most activists would prefer that lawmakers go ahead and just pass a
legalization bill—because running a public education campaign to ensure a
ballot measure passes would be expensive at a time when resources are
needed in other states. A general referendum question would also require
subsequent implementation legislation, and even putting it on the
ballot in time for 2020 would take a supermajority of 75 percent of
legislators.
Florida
Florida voters approved a constitutional amendment to legalize
medical cannabis in 2016. Now, a group called Make It Legal Florida is
working to place a full-scale marijuana legalization measure on the key swing state’s 2020 presidential ballot.
The proposed amendment to the state constitution would allow adults
21 and over to possess up to 2.5 ounces of cannabis. Existing medical
marijuana dispensaries would be permitted to sell marijuana to adults.
While the measure doesn’t mention a licensing system to establish
separate recreational shops, lawmakers will likely enact detailed
regulations should it pass, as they did with the prior medical cannabis
measure.
The campaign is being backed by cannabis companies such as MedMen and Parallel (formerly known as Surterra Wellness).
A separate group, Regulate Florida, recently acknowledged that its
lesser-funded effort wouldn’t be be able to successfully collect enough
signatures to qualify for the ballot.
Idaho
Idaho is one of only a handful of states in the U.S. that doesn’t
even allow patients to access CBD medications with low-THC content. That
could change, however, under a proposed medical marijuana ballot
measure for which activists are currently collecting signatures.
The Idaho Cannabis Coalition’s
proposal would let approved patients and their caregivers possess up to
four ounces of marijuana. A system of licensed and regulated growers,
processors, testers and retail dispensaries would be established.
Patients would not be allowed to grow their own medicine unless they
qualify for a hardship exemption for those who have have a physical,
financial or distance difficulty in acquiring marijuana at a dispensary.
Those patients could grow up to six plants.
Organizers need to collect 55,057 valid signatures from voters in order to qualify the measure for the ballot.
If the initiative is approved, patients with any of 22
conditions—including cancer, chronic pain and post-traumatic stress
disorder—be allowed to possess up to 2.5 ounces of cannabis per 14-day
period.
The secretary of state is expected to announce whether organizers
collected a sufficient number of signatures for ballot access early in
2020.
Now, activists are looking to expand on that with a broader marijuana
legalization. Several different proposed measures to end cannabis
prohibition have been filed
with the secretary of state, but the campaigns at this point seem to be
operating largely under the radar, so it remains to be seen whether any
group will have the funding needed to mount a successful signature
gathering drive.
Last year three separate medical cannabis measures ended up qualifying for the ballot, but two were rejected by voters.
Montana
Montana already has a medical cannabis program, and activists are
looking to expand that to include legal adult use of marijuana in 2020.
The group New Approach Montana is currently in the process of drafting two separate legalization measures—one constitutional and one statutory.
The details of the proposals aren’t yet publicly available, but the
statutory proposal will need roughly 25,500 valid voters signatures to
qualify for ballot access, while the constitutional amendment would
require nearly 51,000 signatures.
The national groups Marijuana Policy Project and New Approach PAC are backing the effort.
A separate group, MontanaCan, has already filed its own legalization proposal.
Under the referendum adopted by the Senate and Assembly, the November
2020 ballot will contain a question that reads, “Do you approve
amending the Constitution to legalize a controlled form of marijuana
called cannabis?â€
If the proposed constitutional amendment is approved, lawmakers would
then get to work adopting regulations for the legal cannabis industry.
New York
Gov. Andrew Cuomo (D) put marijuana legalization language in his
budget submission earlier this year but, despite support for the idea
from leading lawmakers, disagreement over particulars such as how to
spend tax revenue meant that the proposal didn’t get over the finish
line.
“The opposition Senate position is there is no state that has passed
it without a referendum. It’s never been done just by the legislature,â€
he said in a radio interview this year. “I believe Jersey may be moving
to a referendum also, but Massachusetts, et cetera, the legislature
acted after a referendum. So that’s what the senators who oppose it
say—they think it’s an overreach by the legislature.â€
If lawmakers can’t agree on the details of legalization again this
year, Cuomo may call skittish legislators’ bluff and seek to advance a
cannabis referendum to fulfill what he has said is one of his top agenda
items.
North Dakota
North Dakota voters approved a medical cannabis ballot measure in
2016 and two years later swiftly defeated a proposal to more broadly
legalize marijuana.
But advocates may have another chance in 2020.
While the unsuccessful 2018 measure contained no limits on the amount
of cannabis people could possess or grow, the new initiative, written by
the same group of activists, has robust regulations—including a ban on
home cultivation.
Legalization supporters hope more voters will agree to the narrower proposal this time around.
There is also another proposed legalization measure vying to collect the 13,452 valid signatures needed for ballot access.
Ohio
In 2015, Ohio voters overwhelmingly rejected a marijuana legalization
measure that even many longtime activists opposed due its proposed
regulatory structure that would have granted control over cannabis
cultivation to the very same group of wealthy individuals who paid to
put it on the ballot.
Advocates have cited the Buckeye State as a potential target for another try in 2020, though no proposals have yet been filed.
Voters in number of communities throughout the state have in recent years approved measures to decriminalize marijuana possession on a local basis, indicating that there is public support for cannabis reform if placed on the state ballot again next year.
That said, Ohio is a large state, and qualifying initiatives there is
very expensive, so any successful effort will likely need to have
industry support.
Backed by the national New Approach PAC, the new effort will have to
collect 178,000 valid signatures from registered voters to qualify for
ballot access.
Under the measure as initially filed, adults 21 and older would be
allowed to possess, cultivate and purchase cannabis from licensed
retailers. There would be a 15 percent excise tax on marijuana sales,
revenue from which would cover implementation costs and fund schools,
drug treatment programs and other public service programs.
Personal possession would be capped at one ounce and individuals
could grow up to six plants. The proposal would also provide
expungements for those with prior marijuana convictions.
Backers recently withdrew
the initial measure, but plan to redraft it with feedback from the
medical cannabis community, with a new version expected to be filed
soon.
Rhode Island
Lawmakers in Rhode Island have filed marijuana legalization bills for
the last several sessions but they have never been brought to a vote.
In 2019, Gov. Gina Raimondo (D) went so far as to put legalization language in her budget proposal, but it was removed by legislative leaders.
The governor has indicated she will make another attempt in 2020, but if that doesn’t pan out, lawmakers may consider putting the question to voters via a referendum.
In 2016, Raimondo said she is “open to†giving voters a chance to
decide on legalization via a ballot question. And House Speaker Nicholas
Mattiello (D), said that he was “considering the possibility of placing
a non-binding referendum question on the ballot regarding the use of
recreational marijuana.â€
A bill for a marijuana referendum
that was filed in 2018 never received a vote, but it’s an avenue the
legislature might consider pursuing next year as legalization comes
online in more nearby states.
Nebraska
Lawmakers in Nebraska have repeatedly rejected medical cannabis
legislation. Frustrated with their colleagues’ unwillingness to change
the law to let patient legally medicate, two senators in the state’s
unicameral legislature are partnering with local and national advocacy
groups to put the question directly to voters through a ballot initiative.
Under the proposed constitutional amendment,
physicians or nurse practitioners would be able to issue
recommendations to patients, who would then be allowed to “use, possess,
access, and safely and discreetly produce an adequate supply of
cannabis, cannabis preparations, products and materials, and
cannabis-related equipment to alleviate diagnosed serious medical
conditions without facing arrest, prosecution, or civil or criminal
penalties.â€
The measure would also provide for a system of legal and regulated cannabis distribution through dispensaries.
Organizers must collect valid signatures from roughly 122,000 voters in order to make the ballot.
South Dakota
The South Dakota secretary of state’s office certified this month that activists collected more than enough signatures to qualify a medical cannabis measure for the November 2020 ballot.
If approved, patients suffering from debilitating medical conditions
would be allowed to possess and purchase up to three ounces of marijuana
from a licensed dispensary with approval from their doctors. They could
also grow at least three plants, or more if authorized by a physician.
That measure would allow adults 21 and older to possess and
distribute up to one ounce of marijuana and cultivate up to three
cannabis plants. The state Department of Revenue would issue licenses
for manufacturers, testing facilities and retailers.
South Dakota voters rejected medical cannabis ballot measures in 2006
and 2010, but advocates hope that the changing national and regional
climate on marijuana reform means that voters will be more supportive
this time around.
Non-Marijuana Initiatives On State Ballots
Activists in a few states are taking steps to bring broader drug policy reform questions to voters’ ballots in 2020.
A group called Decriminalize California is preparing to soon begin collecting signatures in support of a measure to legalize psilocybin mushrooms.
Separate from the huge number of states where cannabis and drug
policy reform questions could appear before voters on ballots, lawmakers
in many states are expected to consider bills to legalize marijuana.
And with presidential candidates increasingly embracing cannabis
legalization and other far-reaching reforms, 2020 is poised to be the
biggest year for marijuana yet.
“In 2020, hundreds of thousands of Americans will turn out to vote
not for the top of the ticket, but for the rights of cannabis consumers
in upwards of a dozen states,†said NORML Political Director Justin
Strekal. “As we have seen in previous elections, marijuana initiatives
increase voter turnout in nearly every demographic. With public support
growing by the day, 2020 will be the biggest year yet for expanding the
freedoms and liberties of cannabis consumers.â€
Posted by AGORACOM-JC
at 10:47 AM on Monday, December 23rd, 2019
Spyder has two current Development Permits in Calgary, Alberta to build cannabis retail stores and has received the building permit for one of the two locations
The second building permit has been submitted and awaiting approval
Vaughan, Ontario–(December 23, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder Cannabis” or the “Company“), an established Canadian cannabis accessory and an alternative to smoking retailer, provides an update to the corporate business development. Founded in 2014 Spyder is an established chain of three high-end alternative to smoking stores and two cannabis accessory stores in Ontario, with locations in Woodbridge, Scarborough, Burlington, Niagara Falls and Pickering. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding platform by pursuing expansion into the legal cannabis market.
Spyder has two current Development Permits in Calgary, Alberta to
build cannabis retail stores and has received the building permit for
one of the two locations. The second building permit has been submitted
and awaiting approval.
Two weeks ago the government of Ontario announced it will abandon the
current lottery system for cannabis retail and move towards an open
licensing system beginning January 6, 2020. Store authorizations will be
issued starting in April, at the rate of 20 per month. Spyder will be
submitting applications on January 6, 2020 for some of the stores
currently operating. These stores are already built out and Spyder does
not expect major renovations will be required to conform to the Ontario
specifications for licenced stores.
Spyder is currently pursuing other locations in Ontario for aggressive expansion of its scalable retail platform.
The Company’s common shares will resume trading on the TSXV at market open on December 24, 2019
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
For more information, please contact:
Spyder Cannabis Inc. Dan Pelchovitz President & Chief Executive Officer Contact: Investor Relations Phone: 1-888-504-SPDR (1-888-504-7737) Email: [email protected]
Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future events or
future performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not historical
facts are intended to identify forward-looking information and are based
on the Company’s current belief or assumptions as to the outcome and
timing of such future events. Actual future results may differ
materially. In particular, this release contains forward-looking
information relating to the satisfaction of the closing conditions
contemplated under the Agreement. Various assumptions or factors are
typically applied in drawing conclusions or making the forecasts or
projections set out in forward-looking information. Those assumptions
and factors are based on information currently available to the Company.
Risk factors that could cause actual results or outcomes to differ
materially from the results expressed or implied by forward-looking
information include, among other things: the TSX Venture Exchange
declining to accept the transaction, the landlord not consenting to the
Lease Assignment, changes in tax laws, general economic and business
conditions; and changes in the regulatory regulation. The Company
cautions the reader that the above list of risk factors is not
exhaustive. The forward-looking information contained in this release is
made as of the date hereof and the Company is not obligated to update
or revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue reliance
on forward-looking information. The foregoing statements expressly
qualify any forward-looking information contained herein.
Posted by AGORACOM-JC
at 2:28 PM on Friday, December 20th, 2019
Spyder Cannabis Announces MOU with HighBreed Growth has Expired
Previously announced Memorandum of Understanding with HighBreed Growth Corp. has expired pursuant to its terms
Under the MOU signed on September 5, 2019, the parties intended to complete a business combination that would result in a reverse take-over of Spyder Cannabis by HGBGC
Company’s common shares will resume trading on the TSXV at market open on December 24, 2019
Vaughan, Ontario–(December 20, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder Cannabis” or the “Company“), an established Canadian cannabis accessory and vape retailer, announces its previously announced Memorandum of Understanding (the “MOU“) with HighBreed Growth Corp. (“HBGC“) has expired pursuant to its terms. Under the MOU signed on September 5, 2019, the parties intended to complete a business combination that would result in a reverse take-over of Spyder Cannabis by HGBGC. Given that the transaction will no longer proceed, the Company does not, at the present time, intend to proceed with a delisting from the TSX Venture Exchange (the “TSXV“).
The Company’s common shares will resume trading on the TSXV at market open on December 24, 2019
About Spyder
Founded in 2014 Spyder is an established chain of three high-end vape
stores in Ontario, with stores located in Woodbridge, Scarborough and
Burlington. The Spyder brand is defined by its high-quality proprietary
line of e-juice, liquids and exclusive retail deals, dispensed in
uniquely designed stores creating the optimal customer experience.
Spyder is building off this leading retail, distribution and branding
eCig and vapes company and is pursuing expansion into the legal cannabis
market. Spyder has developed a scalable retail model with aggressive
expansion plan to create a significant retail footprint with targeted
and
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
For more information, please contact:
Spyder Cannabis Inc. Dan Pelchovitz President & Chief Executive Officer Contact: Investor Relations Phone: 1-888-504-SPDR (1-888-504-7737) Email: [email protected]
Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future events or
future performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not historical
facts are intended to identify forward-looking information and are based
on the Company’s current belief or assumptions as to the outcome and
timing of such future events. Actual future results may differ
materially. In particular, this release contains forward-looking
information relating to the satisfaction of the closing conditions
contemplated under the Agreement. Various assumptions or factors are
typically applied in drawing conclusions or making the forecasts or
projections set out in forward-looking information. Those assumptions
and factors are based on information currently available to the Company.
Risk factors that could cause actual results or outcomes to differ
materially from the results expressed or implied by forward-looking
information include, among other things: the TSX Venture Exchange
declining to accept the transaction, the landlord not consenting to the
Lease Assginment, changes in tax laws, general economic and business
conditions; and changes in the regulatory regulation. The Company
cautions the reader that the above list of risk factors is not
exhaustive. The forward-looking information contained in this release is
made as of the date hereof and the Company is not obligated to update
or revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue reliance
on forward-looking information. The foregoing statements expressly
qualify any forward-looking information contained herein.
Posted by AGORACOM-JC
at 11:47 AM on Thursday, December 19th, 2019
Signed an agreement with Endocanna, to licence and distribute Endo.dna™ test kits through its network of clinics and market directly to the Company’s 165,000 patient database, and as a standard offering in the Sun Valley Health franchise program
Company plans to partner with Endocanna for their Endo.Aligned™ Formulations program to create, manufacture, produce and distribute specialized CBD based products utilizing the Company-Heritage joint venture extraction centre in Sandy, OR.
VANCOUVER, BC / December 19, 2019 / Endocanna Health Inc. (“Endocanna“), a research and development biotechnology company specializing in endocannabinioid DNA testing, and a partly owned subsidiary of Heritage Cannabis Holdings Corp. (CSE:CANN) (“Heritage“) partners with Empower Clinics to distribute Endo.dna™ test kits and develop Endo.Aligned™ product formulations.
EMPOWER CLINICS INC. (CSE:CBDT) (OTC:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, is pleased to announce it has signed an agreement with Endocanna, to licence and distribute Endo.dna™ test kits through its network of clinics and market directly to the Company’s 165,000 patient database, and as a standard offering in the Sun Valley Health franchise program.
In addition, the Company plans to partner with Endocanna for their Endo.Aligned™
Formulations program to create, manufacture, produce and distribute
specialized CBD based products utilizing the Company-Heritage joint
venture extraction centre in Sandy, OR.
“Empower with its clinic network, large patient base and numerous
physicians are an ideal distribution partner for Endocanna,” said Steven
McAuley, Empower’s Chairman and CEO. “As we strive to be a leader in
patient care and efficacy, having deeper insights about our patients
unique DNA profile allows our physicians to provide even more effective
cannabis based treatment options. Then, translating that knowledge into
new product formulations with Endocanna, will greatly enhance the
long-term shareholder value we are creating.”
“We are pleased to collaborate with a life sciences company like
Empower to develop a custom endocannabinoid-based therapeutic efficacy
model,” says Len May, Endocanna Health CEO and founder. “Our goal at
Endocanna Health is to identify and optimize cannabinoid-based therapies
based on an individual’s DNA while mitigating potential adverse-events
and drug interactions. The data will support DNA validation along with
peer-to-peer efficacy feedback, and provides key data to support our
mission in facilitating the highest quality, consistent, personalized,
endo-aligned cannabinoid products.”
The Endo·dna test analyzes specific DNA markers to provide a
personalized report, Endo·Decoded, that can help guide decisions for
choosing the right cannabinoid products with the right:
Formulation – full-spectrum or broad-spectrum
Dose – the amount you take and when you take it
Delivery – flower, aerosol, vaping, sublingual (under the tongue), topical, or edible
The Endo·Decoded report helps consumers uncover optimal cannabinoid
ratios and terpene profiles for their specific genetic makeup.
Endocanna’s customized endocannabinoid genomics super-chip and algorithm
provides consumers with:
Ideal cannabinoid ratios and terpene profiles, methods of delivery or consumption, and dosing.
Suggestions for specific terpenes and cannabinoids to seek out or to avoid.
Individualized risks or benefits from using cannabinoids.
Suggestions commercially available products and brands most aligned with individual genetics and formulations suggestions.
ABOUT EMPOWER CLINICS INC.
Empower is a leading owner/operator of a network of physician-staffed
clinics focused on helping patients improve and protect their health
through innovative uses of medical cannabis. It is expected that
Empower’s proprietary product line “Sollievo” will offer patients a
variety of delivery methods of doctor recommended cannabidiol (CBD)
based product options in its clinics, online and at major retailers.
With over 165,000 patients, an expanding clinic footprint, a focus on
new technologies, including tele-medicine, and an expanded product
development strategy, Empower is undertaking new growth initiatives to
be positioned as a vertically integrated, diverse, market-leading
service provider for complex patient requirement’s in 2019 and beyond.
ABOUT ENDOCANNA HEALTH INC.
Endocanna is a biotechnology research company that utilizes a
patent-pending process for its cannabinoid DNA variant report,
Endo·Decoded™ and product- matching algorithm, Endo·Aligned™. Endo·dna™
provides two ways to submit DNA for analysis, either collected through a
simple saliva swab or a direct upload of genetic data files from
popular DNA testing services like Ancestry, 23andMe, Family TreeDNA, or
MyHeritageDNA. Endocanna’s HIPAA compliant and secure health and
wellness portal, Mydna.live, provides customers with a personalized
experience where they can access their Endo·Decoded report and
Endo·Aligned formulation suggestions for their specific genotype. In
2019, cannabis producer Heritage Cannabis Holdings (CSE:CANN)(OTC:HERTF)
acquired a 30 percent stake in Endocanna Health Inc.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steve Low Boom Capital Markets [email protected] 647-620-5101
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release.Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding: endocanna agreement; the Company’s intention to
open a hemp-based CBD extraction facility; the expected product
development and manufacturing; the expected benefits to the Company and
its shareholders as a result of the proposed JV. Such statements are
only projections, are based on assumptions known to management at this
time, and are subject to risks and uncertainties that may cause actual
results, performance or developments to differ materially from those
contained in the forward-looking statements, including that: Heritage
and Empower may be unable to agree on terms of a definitive agreement
with respect to the JV; that the Company may not open a hemp-based CBD
extraction facility; that legislative changes may have an adverse effect
on the Company’s business and product development; that the Company may
not be able to obtain adequate financing to pursue its business plan;
general business, economic, competitive, political and social
uncertainties; failure to obtain any necessary approvals in connection
with the proposed JV or extraction facility; and other factors beyond
the Company’s control. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if they do
occur, what benefits the Company will obtain from them. Readers are
cautioned not to place undue reliance on the forward-looking statements
in this release, which are qualified in their entirety by these
cautionary statements. The Company is under no obligation, and expressly
disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable securities laws.
SOURCE: Endocanna Health Inc.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Completes Agreement With Heritage Cannabis Subsidiary Endocanna Health $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
Posted by AGORACOM-JC
at 10:12 AM on Wednesday, December 18th, 2019
SPONSOR: PRIMO NUTRACEUTICALS INC.
(CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV)
provides strategic capital to the thriving cannabis cultivation
sector through ownership and development of commercial real estate
properties. The company also offers fully built out turnkey facilities
equipped with state-of-the-art growing infrastructure to cannabis
growers and processors. Click here for more info.
Lawmakers pressure FDA to make clear guidelines on CBD
With the passing of the 2018 Farm Bill, farmers, manufacturers and consumers are keeping a watchful eye on the agency and how they might address compliance for the thousands of companies selling the product and the millions of consumers vying to use it.Â
June 25, 2019, Senator Ron Wyden sent a letter to the Department of Health and Human Services and the Food and Drug  Administration urging both entities to provide clarity around CBD products derived from hemp.
The FDA has been under a magnifying glass since hemp was declassified
as a schedule I drug, having formerly fallen under the thumb of the
Controlled Substances Act of 1970.
With the passing of the 2018 Farm Bill, farmers, manufacturers and
consumers are keeping a watchful eye on the agency and how they might
address compliance for the thousands of companies selling the product
and the millions of consumers vying to use it.
Yet silence and lack of clarification on a potential path towards
compliance for supplement producers has left many chomping at the bit
for the agency to come up with regulatory guidelines for selling Food
and dietary supplements containing CBD. In the interim, well-established
companies such as Next Green Wave, Inc. (Next
Green Wave, NGW:CSE | NXGWF:OTCQX) have continued to solidify their
position in the market, ready and able to serve the exponentially
growing demand of what promises to be a $20 plus billion-dollar
industry.
A Slow and Arduous Process
In Wyden’s letter, the lawmaker criticized the FDA’s indication that
it could take up to 3 to 5 years for the FDA to implement final
regulations for companies to lawfully sell CBD infused foods, calling
the suggestion “unacceptable.†Wyden wrote that he urges the FDA to
quickly implement “enforcement discretion guidelines†by August 1, then
issue an interim final rule pending a permanent rule so that companies
will have clarity on how CBD in food and dietary products will be
regulated.
This argument may have fallen on attentive ears, but as of the date
of this publication, the FDA has yet to provide any clear established
guidelines. Although the agency has wielded their powers against a
handful of “bad actorsâ€, their approach seems to be that of “wait and
see†with regards to due process.
The letter penned by Wyden also stressed the economic impact growers
in states like Oregon would benefit from by allowing CBD to be in more
products, but are halted until the FDA gives the okay that CBD in
ingestible products is lawful to sell and okay to use.
However, this isn’t the first letter Wyden
has sent to the agency regarding a regulatory pathway to CBD
commercialization. In January the lawmaker co-authored a letter with
Senator Jeff Merkley telling the FDA they must revamp current
legislation around offering CBD products. Both senators advised former
commissioner Scott Gottlieb to “immediately begin updating regulations
for hemp-derived CBD and other hemp-derived cannabinoids, and give U.S.
producers more flexibility in the production, consumption, and sale of
hemp products,†according to the letter.
FDA is listening to public demand for clear CBD regulations
The FDA has slowly but surely has been taking measures to develop
guidelines around selling CBD ingestible-products. In late May, the
agency held a public hearing allowing stakeholders the opportunity to
share their reasons why the FDA-regulation for CBD food and dietary
products is crucial, according to the Chicago Tribune.
The agency also gave a chance for the public to weigh in on CBD
regulation by opening a public docket for individuals to add comments.
The deadline to submit comments was July 16, and the agency received
over 3,000 comments, according to the Chicago Tribune. In conjunction
with the open docket, the FDA also published an article July 17 echoing the agency’s stance on CBD and concern for public safety.
“We recognize that there is significant public interest in these
products, for therapeutic purposes and otherwise,†the article said. “At
the same time, there are many unanswered questions about the science,
safety, and quality of many of these products. As we approach these
questions, we do so as a science-based regulatory agency committed to
our mission of protecting and promoting public health.â€
In the “Listening to and learning from stakeholders†section of the
article, the FDA insists that relative questions must be answered in
order to develop a clear pathway to regulate CBD products which include
the following:
How much CBD is safe to consume in a day? How does it vary depending on what form it’s taken?
Are there drug interactions that need to be monitored?
What are the impacts on special populations, like children, the elderly, and pregnant or lactating women?
What are the risks of long-term exposure?
In a second article published on the same day, the FDA stressed it has not approved any CBD products besides Epidiolex,
a drug which treats seizures caused by epilepsy. And is currently
working to figure out how CBD will affect body parts, special
populations and pets.
Since both the public hearing and window to submit comments to the
FDA have both passed, the agency says it will review submitted
information and intends to follow up with its findings “around the end
of summer/early fall,†according to the Chicago Tribune.
It is unclear if the FDA will tentatively meet this deadline, but the
agency will most likely continue to be pressured by lawmakers and the
public to provide a regulatory framework around the selling and
obtaining CBD food and dietary supplements.
Posted by AGORACOM-JC
at 10:27 AM on Tuesday, December 17th, 2019
SPONSOR: PRIMO NUTRACEUTICALS INC.
(CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV)
provides strategic capital to the thriving cannabis cultivation
sector through ownership and development of commercial real estate
properties. The company also offers fully built out turnkey facilities
equipped with state-of-the-art growing infrastructure to cannabis
growers and processors. Click here for more info.
Here’s Why Dollar General Has High Hopes for CBD
By: Rich Duprey
Dollar General (NYSE: DG) is jumping on the CBD bandwagon, announcing it intends to start selling products infused with cannabidiol in 1,100 stores across seven states by spring 2020
Limiting its selection of goods to topical products such as creams, ointments, bath bombs, bath salts, and face masks. Edibles are not part of the plan.
Yet where grocery stores, shoe stores, pharmacies, and wellness stores
have all previously said they, too, were joining the conga line of
retailers selling CBD products, the dollar store chain’s entry has a
greater chance of boosting its bottom line.
Image source: Getty Images.
Business is growing like a weed
Unlike many other retailers and even rival Dollar Tree, Dollar General is on fire, giving a master class in discount retailing
in the third quarter. Sales rose 9% to $7 billion on a near-5% increase
in comparable-store sales, generating a 13% rise in earnings per share.
Management also raised top- and bottom line guidance for the year.
It was tough to pick out a category that was best, as it saw
across-the-board sales increases, but it was enough for the discount
chain to know it needed to pick up the pace of expansion. Where it
expects to open 975 new stores this year, it plans on opening another
1,000 in 2020. In all, Dollar General will be involved in 20% more real
estate projects next year than it was this year.
That’s important because as it continues to reach further into all
regions of the country, getting closer to its target customer, CBD
products afford it the opportunity to accelerate that growth.
The madness of cannabis
Marijuana,
cannabis, and cannabidiol all live in a legal purgatory. Although a
number of states have legalized marijuana for personal use, it
officially remains a controlled dangerous substance at the federal
level.
Cannabis, on the other hand, essentially comprises two categories,
marijuana and hemp, with the major difference being the presence of
tetrahydrocannabinol, or THC, the psychoactive compound that gets a user
high. While hemp does contain THC, it is at very low levels and not
enough to get someone high. The 2018 Farm Bill removed hemp and hemp-derived products from its list of controlled dangerous substances.
CBD is one of over 100 compounds found in cannabis, but unlike THC,
it doesn’t get you high. Also, where marijuana has very little CBD, hemp
has a lot. Many also believe CBD has a variety of therapeutic
properties, and though some studies have seemingly backed up the claim,
there haven’t been very many studies, and the long-term implications
from its use are still unknown.
A green business
The Food and Drug Administration is slow-walking the
formulation of a coherent policy on CBD, which has put many retailers
in limbo on just how best to proceed. What the FDA was clear about in
its recent policy update, however, was that it is illegal to add CBD to
food or supplements. That’s why you see retailers opting for topical
applications of the compound.
Cannabidiol has another benefit for the retail industry in that it
enjoys over dried cannabis, or so-called legal weed. Consumers have
demonstrated willingness to pay up for the compound, and there is a
plentiful supply of CBD, suggesting profits will remain stable.
That’s an attractive feature for low-margin businesses like grocery
stores. But Dollar General, which sells merchandise at many different
price points, tends to make up in volume what it loses out in product
markups. Driving down the cost of CBD-infused products could cause
consumers to flock to its stores.
And for a discount chain, Dollar General is a relatively
high-profit-margin business. Over the past five years, its operating
margins stand at almost 9% and net margins are 6%. But compare that with
other retailers that have announced they will be selling CBD products.
Retailer
5-Year Operating Margin
5-Year Net Margin
Dollar General
8.9%
6%
Dollar Tree
8.4%
2.5%
CVS Health
5.6%
2.6%
Rite Aid
1.6%
2.1%
Walgreens
4.6%
3.5%
Kroger
2.6%
1.9%
Data source: Morningstar.
A smoking hot opportunity
The retail market is expected to be the biggest contributor
to CBD’s growth, accounting for 60% of the forecast $20 billion in
annual sales. Dollar General has the potential to bring CBD products to
more people and attract a bigger share of the market because of its
value proposition.
While there may be questions about the viability and efficacy of the
CBD in the products it offers (a question that looms over all retailers
selling CBD products), CBD has a higher chance of moving the needle for
Dollar General than it does for anyone else.
Source: https://www.nasdaq.com/articles/heres-why-dollar-general-has-high-hopes-for-cbd-2019-12-17